Clinically Validated Probiotics
Complex Journey from Innovation to Patient impact
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Elevating Drug Safety
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia
Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries
Articles
Perspectives on the Vaccine Industry
Article talks about the key findings on the study conducted by Merck on the future of vaccine manufacturing in the AsiaPacific region
Research Insights
CRISPR-Analytics (CRISPR-A): A Platform for Precise Analytics and Simulations for Gene Editing
CRISPRbased gene editing has become a fundamental toolbox to cover a large variety of research and applied needs
Case Studies
Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly
Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha
Techno Trends
Alnylam Introduced First and Only AMVUTTRA® (vutrisiran) for ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
Alnylam Pharmaceuticals has AMVUTTRA vutrisiran as the first and only FDAapproved treatment for adults with ATTR Amyloidosis with Cardiomyopathy ATTRCM to reduce cardiovascular mortality hospitalisations and urgent heart failure visits
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
APAC’s Biopharma Providers’ Role in Pioneering a Healthcare Revolution
Narayana is responsible for leading the overall business, P&L, strategy, and program management for Avantor’s Biopharma Business Unit in AMEA. He possesses close to two decades of comprehensive experience in international markets, leading diverse teams in account, product, sales and business management, and delivering strategic solutions for Consumables, systems and Instruments in Academic, Pharmaceuticals, Bioprocessing, and Bioresearch Industries.
Syringe-like Bacterial Nanomachine Emerges as Potential Therapeutics Delivery Device
I am Chanchal Kumawat. I started my journey in science as Ph.D. student at Regional Centre for Biotechnology and continued as postdoctoral fellow at Max Perutz labs, Austria. I enjoyed making scientific discoveries in the laboratory and now, enjoy communicating it as a science writer.
The Use of AI in Pharmacovigilance
Dr. Alejandra Guerchicoff is a Ph.D. in Molecular Genetics with postdoctoral training in Molecular Cardiology and Genetics of Cardiac Arrhythmias. She works as an Industry Advisor for the TCS ADD™ platform with the Life Sciences unit at TCS. Dr. Guerchicoff has over 20 years of experience in clinical research and post-marketing pharmacovigilance for medical devices, drugs, combination products, gene and cell therapy, and software for medical device products. She has authored many prestigious journal publications and books on diverse subjects and therapeutic areas. In her current role, Dr. Guerchicoff works on developing innovative technology solutions with AI and other modern technologies across various life sciences operations.
Pharma Regulatory Bottlenecks and Vaccination Delays
Sonam Chandwani is the Managing Partner at KS Legal & Associates. Her experience encompasses commercial and crosses border transactions across various sectors, advising both Indian companies in their outbound investments and foreign companies investing in India, on diverse areas of Indian laws concerning Mergers & Acquisitions, Insolvency & Bankruptcy, Banking & Finance, Real Estate, Arbitration and Litigation in Courts and Tribunals on a PAN-India basis.
The Role of Bioinformatics in Accelerating Translational Research
Vasundhara Dauneria is a biotechnology professional with over six years of experience spanning genomics, next-generation sequencing, and bioinformatics. She has worked across wet-lab and computational research environments, with hands-on expertise in NGS workflows, assay development, and multi-omics data analysis. Her work focuses on applying data-driven approaches to support translational research and precision medicine initiatives.
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
